Restricted accessResearch articleFirst published online 2026-2
Reveal the mechanism of action of donepezil combined with nimodipine in the treatment of Alzheimer's disease via metabolomics and lipidomics analyses in rats
With the aging population, the number of Alzheimer's disease (AD) patients has been increasing annually, creating an urgent need for AD therapeutic drugs. Donepezil combined with nimodipine (DN) has demonstrated therapeutic potential in the treatment of AD, but its mechanism of action remains unclear.
Objective
To reveal the mechanism of DN in the treatment of AD rats.
Methods
The AD rat model was established and evaluated by behavioral experiments and pathology. The therapeutic mechanism of DN in AD treatment was investigated through lipidomics and hippocampal metabolomics analyses based on ultra-high-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-Q-TOF/MS).
Results
The learning and memory ability of AD rats can be improved after DN treatment. Significant changes were observed in 40 serum lipid metabolites and 19 hippocampal metabolites. These metabolites are mainly involved in glycerophospholipid metabolism, sphingolipid metabolism, amino acid metabolism, unsaturated fatty acid metabolism and other processes in AD rats.
Conclusions
DN could improve cognitive function and nerve damage in AD rats. It may plays a therapeutic role in AD rats by regulating cholinergic damage, Ca2+ overload, oxidative stress, neuroinflammation, and energy deficiency caused by metabolic disorders, which has practical significance for further research and clinical application of DN.
LiuEZhangYWangJZ. Updates in Alzheimer's disease: from basic research to diagnosis and therapies. Transl Neurodegener2024; 13: 45.
2.
TenchovRSassoJMZhouQA. Alzheimer's disease: exploring the landscape of cognitive decline. ACS Chem Neurosci2024; 15: 3800–3827.
3.
XuLWangZLiM, et al.Global incidence trends and projections of Alzheimer disease and other dementias: an age-period-cohort analysis 2021. J Glob Health2025; 15: 04156.
4.
Trejo-LopezJAYachnisATProkopS. Neuropathology of Alzheimer's disease. Neurotherapeutics2022; 19: 173–185.
5.
SrivastavaSAhmadRKhareSK. Alzheimer's disease and its treatment by different approaches: a review. Eur J Med Chem2021; 216: 113320.
6.
WellerJBudsonA. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Res2018; 7: 1161.
7.
BreijyehZKaramanR. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules2020; 25: 5789.
8.
WangJ. Clinical effect of donepezil combined with nimodipine in the treatment of Alzheimer's disease. J Chronic Dis2020; 21: 177–179.
9.
BirksJSHarveyRJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev2018; 6: CD001190.
10.
CarlsonAPHänggiDMacdonaldRL, et al.Nimodipine reappraised: an old drug with a future. Curr Neuropharmacol2020; 18: 65–82.
11.
GuanPPCaoLLWangP. Elevating the levels of calcium ions exacerbate Alzheimer's disease via inducing the production and aggregation of β-amyloid protein and phosphorylated tau. Int J Mol Sci2021; 22: 5900.
12.
TongBCWuAJLiM, et al.Calcium signaling in Alzheimer's disease & therapies. Biochim Biophys Acta Mol Cell Res2018; 1865: 1745–1760.
13.
QiuSGuoSYangQ, et al.Innovation in identifying metabolites from complex metabolome-highlights of recent analytical platforms and protocols. Front Chem2023; 11: 1129717.
14.
XuLLiuYWuH, et al.Rapid identification of absorbed components and metabolites of Gandou decoction in rat plasma and liver by UPLC-Q-TOF-MS(E). J Chromatogr B Analyt Technol Biomed Life Sci2020; 1137: 121934.
15.
HanRWangMWangL, et al.GC/MS-based urine metabolomics study on the ameliorative effect of xanthoceras sorbifolia extract on Alzheimer's disease in mice. Evid Based Complement Alternat Med2022; 2022: 3390034.
16.
Gonzalez-RianoCGarciaABarbasC. Metabolomics studies in brain tissue: a review. J Pharm Biomed Anal2016; 130: 141–168.
17.
PlutaRJanuszewskiSCzuczwarSJ. Post-ischemic neurodegeneration of the hippocampus resembling Alzheimer's disease proteinopathy. Int J Mol Sci2021; 23: 306.
18.
JaroudiWGaramiJGarridoS, et al.Factors underlying cognitive decline in old age and Alzheimer's disease: the role of the hippocampus. Rev Neurosci2017; 28: 705–714.
19.
QiuSCaiYYaoH, et al.Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther2023; 8: 132.
20.
LiuYLiuZWeiM, et al.Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer's disease. Food Funct2019; 10: 432–447.
21.
AkyolSUgurZYilmazA, et al.Lipid profiling of Alzheimer's disease brain highlights enrichment in glycerol(phospho)lipid, and sphingolipid metabolism. Cells2021; 10: 2591.
22.
FurseSde KroonAI. Phosphatidylcholine's functions beyond that of a membrane brick. Mol Membr Biol2015; 32: 117–119.
23.
WurtmanRJ. How anticholinergic drugs might promote Alzheimer's disease: more amyloid-β and less phosphatidylcholine. J Alzheimers Dis2015; 46: 983–987.
24.
ChalimoniukM. Secretory phospholipase A2 and its role in oxidative stress and inflammation. Postepy Biochem2012; 58: 204–208.
25.
PatelDWittSN. Ethanolamine and phosphatidylethanolamine: partners in health and disease. Oxid Med Cell Longev2017; 2017: 4829180.
26.
LiQLiuYSunM. Autophagy and Alzheimer's disease. Cell Mol Neurobiol2017; 37: 377–388.
27.
AshleighTSwerdlowRHBealMF. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimers Dement2023; 19: 333–342.
28.
CascellaRCecchiC. Calcium dyshomeostasis in Alzheimer's disease pathogenesis. Int J Mol Sci2021; 22: 4941.
29.
PalamiucLRaviAEmerlingBM. Phosphoinositides in autophagy: current roles and future insights. FEBS J2020; 287: 222–238.
30.
XuLHeDBaiY. Microglia-Mediated inflammation and neurodegenerative disease. Mol Neurobiol2016; 53: 6709–6715.
31.
GladeMJSmithK. Phosphatidylserine and the human brain. Nutrition2015; 31: 781–786.
32.
ZhuangJZhangYShuH, et al.Phosphatidylserine in the nervous system: cytoplasmic regulator of the AKT and PKC signaling pathways and extracellular “eat-me” signal in microglial phagocytosis. Mol Neurobiol2023; 60: 1050–1066.
33.
KimHYHuangBXSpectorAA. Phosphatidylserine in the brain: metabolism and function. Prog Lipid Res2014; 56: 1–18.
34.
GaultCRObeidLMHannunYA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol2010; 688: 1–23.
35.
GoñiFMAlonsoA. Sphingomyelinases: enzymology and membrane activity. FEBS Lett2002; 531: 38–46.
36.
Jazvinšćak JembrekMHofPRŠimićG. Ceramides in Alzheimer's disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxid Med Cell Longev2015; 2015: 346783.
37.
LeeJKJinHKParkMH, et al.Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. J Exp Med2014; 211: 1551–1570.
38.
Kogot-LevinASaadaA. Ceramide and the mitochondrial respiratory chain. Biochimie2014; 100: 88–94.
39.
ChowdhuryMRJinHKBaeJS. Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease. Biomedicines2022; 10: 1956.
40.
AyubMJinHKBaeJS. Novelty of sphingolipids in the central nervous system physiology and disease: focusing on the sphingolipid hypothesis of neuroinflammation and neurodegeneration. Int J Mol Sci2021; 22: 7353.
41.
CouttasTAKainNDanielsB, et al.Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun2014; 2: 9.
42.
KannoTNishizakiTProiaRL, et al.Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampus. Neuroscience2010; 171: 973–980.
43.
Asle-RoustaMKolahdoozZOryanS, et al.FTY720 (fingolimod) attenuates beta-amyloid peptide (Aβ42)-induced impairment of spatial learning and memory in rats. J Mol Neurosci2013; 50: 524–532.
44.
FernstromJDFernstromMH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr2007; 137: 1539S.
45.
LiuPYangQYuN, et al.Phenylalanine metabolism is dysregulated in human hippocampus with Alzheimer's disease related pathological changes. J Alzheimers Dis2021; 83: 609–622.
46.
WissmannPGeislerSLeblhuberF, et al.Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations. J Neurol Sci2013; 329: 29–33.
47.
Ramírez-GuerreroSGuardo-MayaSMedina-RincónGJ, et al.Taurine and astrocytes: a homeostatic and neuroprotective relationship. Front Mol Neurosci2022; 15: 937789.
48.
WidnerBLeblhuberFWalliJ, et al.Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol1999; 467: 133–138.
49.
WlodarskaMLuoCKoldeR, et al.Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe2017; 22: 25–37.
50.
BrewerGJWallimannTW. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem2000; 74: 1968–1978.
51.
ForbesSCCordingleyDMCornishSM, et al.Effects of creatine supplementation on brain function and health. Nutrients2022; 14: 921.
52.
RajKGuptaGDSinghS. Spermine protects aluminium chloride and iron-induced neurotoxicity in rat model of Alzheimer's disease via attenuation of tau phosphorylation, Amyloid-β (1-42) and NF-κB pathway. Inflammopharmacology2021; 29: 1777–1793.
53.
WuGBazerFWBurghardtRC, et al.Proline and hydroxyproline metabolism: implications for animal and human nutrition. Amino Acids2011; 40: 1053–1063.
54.
AnsoleagaBJovéMSchlüterA, et al.Deregulation of purine metabolism in Alzheimer's disease. Neurobiol Aging2015; 36: 68–80.
55.
Kaddurah-DaoukRRozenSMatsonW, et al.Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement2011; 7: 309–317.
56.
TeixeiraFCGutierresJMSoaresMSP, et al.Inosine protects against impairment of memory induced by experimental model of Alzheimer disease: a nucleoside with multitarget brain actions. Psychopharmacology (Berl)2020; 237: 811–823.
57.
TeixeiraFCSoaresMSPBlödornEB, et al.Investigating the effect of inosine on brain purinergic receptors and neurotrophic and neuroinflammatory parameters in an experimental model of Alzheimer's disease. Mol Neurobiol2022; 59: 841–855.
58.
GomesCVKasterMPToméAR, et al.Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta2011; 1808: 1380–1399.
59.
AnguloECasadóVMallolJ, et al.A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol2003; 13: 440–451.
60.
OwenOEKalhanSCHansonRW. The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem2002; 277: 30409–30412.
61.
XuJPatassiniSBegleyP, et al.Cerebral deficiency of vitamin B5 (d-pantothenic acid; pantothenate) as a potentially-reversible cause of neurodegeneration and dementia in sporadic Alzheimer's disease. Biochem Biophys Res Commun2020; 527: 676–681.
62.
YinFSanchetiHPatilI, et al.Energy metabolism and inflammation in brain aging and Alzheimer's disease. Free Radic Biol Med2016; 100: 108–122.
63.
KandelPSemerciFMishraR, et al.Oleic acid is an endogenous ligand of TLX/NR2E1 that triggers hippocampal neurogenesis. Proc Natl Acad Sci U S A2022; 119: e2023784119.
64.
ShahidiFAmbigaipalanP. Omega-3 polyunsaturated fatty acids and their health benefits. Annu Rev Food Sci Technol2018; 9: 345–381.
ChoqueBCathelineDRiouxV, et al.Linoleic acid: between doubts and certainties. Biochimie2014; 96: 14–21.
67.
Alarcon-GilJSierra-MagroAMorales-GarciaJA, et al.Neuroprotective and anti-inflammatory effects of linoleic acid in models of Parkinson's disease: the implication of lipid droplets and lipophagy. Cells2022; 11: 2297.
